Aquestive Therapeutics (AQST) Competitors

$3.28
+0.06 (+1.86%)
(As of 05/16/2024 ET)

AQST vs. PROC, NBTX, EPIX, FBLG, URGN, VNDA, NLTX, CRMD, ORGO, and AKBA

Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Procaps Group (PROC), Nanobiotix (NBTX), ESSA Pharma (EPIX), FibroBiologics (FBLG), UroGen Pharma (URGN), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), CorMedix (CRMD), Organogenesis (ORGO), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.

Aquestive Therapeutics vs.

Procaps Group (NASDAQ:PROC) and Aquestive Therapeutics (NASDAQ:AQST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.

Procaps Group has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Procaps Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Procaps Group$409.92MN/A$42.54M$0.524.96
Aquestive Therapeutics$50.58M5.90-$7.87M-$0.42-7.81

Procaps Group has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the S&P 500.

Procaps Group presently has a consensus target price of $4.50, indicating a potential upside of 74.42%. Aquestive Therapeutics has a consensus target price of $8.00, indicating a potential upside of 143.90%. Given Procaps Group's stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Procaps Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Procaps Group
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aquestive Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

Procaps Group has a net margin of 12.61% compared to Procaps Group's net margin of -55.85%. Aquestive Therapeutics' return on equity of 283.06% beat Procaps Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Procaps Group12.61% 283.06% 11.04%
Aquestive Therapeutics -55.85%N/A -37.93%

32.5% of Aquestive Therapeutics shares are owned by institutional investors. 19.9% of Procaps Group shares are owned by company insiders. Comparatively, 8.4% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 9 more articles in the media than Procaps Group. MarketBeat recorded 13 mentions for Aquestive Therapeutics and 4 mentions for Procaps Group. Procaps Group's average media sentiment score of 0.48 beat Aquestive Therapeutics' score of 0.22 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Procaps Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aquestive Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aquestive Therapeutics received 195 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 66.67% of users gave Aquestive Therapeutics an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.

CompanyUnderperformOutperform
Procaps GroupOutperform Votes
3
37.50%
Underperform Votes
5
62.50%
Aquestive TherapeuticsOutperform Votes
198
66.67%
Underperform Votes
99
33.33%

Summary

Aquestive Therapeutics beats Procaps Group on 10 of the 18 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AQST vs. The Competition

MetricAquestive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$298.61M$6.71B$5.10B$7.96B
Dividend YieldN/A2.74%37.28%3.93%
P/E Ratio-7.8123.26170.6118.77
Price / Sales5.90256.332,313.6479.11
Price / CashN/A35.2335.8831.19
Price / Book-8.206.395.464.47
Net Income-$7.87M$138.12M$105.10M$217.14M
7 Day Performance-0.30%0.28%1.65%1.88%
1 Month Performance-14.81%2.51%3.86%5.32%
1 Year Performance56.19%0.64%7.85%11.55%

Aquestive Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PROC
Procaps Group
1.7707 of 5 stars
$2.74
-2.5%
$4.50
+64.2%
-41.8%$309.13M$414.10M5.275,500
NBTX
Nanobiotix
1.8538 of 5 stars
$6.41
+1.4%
$11.00
+71.6%
+55.9%$302.10M$39.18M0.00101Positive News
Gap Up
EPIX
ESSA Pharma
2.1474 of 5 stars
$6.82
-2.3%
$16.50
+141.9%
+112.3%$301.72MN/A-11.5650Analyst Forecast
Short Interest ↑
News Coverage
FBLG
FibroBiologics
0 of 5 stars
$9.22
+5.5%
N/AN/A$300.89MN/A0.0010News Coverage
URGN
UroGen Pharma
3.908 of 5 stars
$13.45
-2.9%
$46.67
+247.0%
+16.7%$315.40M$82.71M-3.61198Analyst Forecast
Analyst Revision
News Coverage
VNDA
Vanda Pharmaceuticals
1.1405 of 5 stars
$5.48
+13.2%
N/A-15.2%$318.94M$192.64M109.62203Gap Up
High Trading Volume
NLTX
Neoleukin Therapeutics
0 of 5 stars
$33.94
+3.4%
$30.00
-11.6%
+94.2%$318.97MN/A-10.917
CRMD
CorMedix
1.5521 of 5 stars
$5.84
-0.8%
$13.00
+122.6%
+1.9%$320.10M$60,000.00-6.3582Analyst Forecast
Short Interest ↑
ORGO
Organogenesis
4.0412 of 5 stars
$2.44
+2.1%
$4.83
+98.1%
-6.6%$321.98M$433.14M61.02862Earnings Report
High Trading Volume
AKBA
Akebia Therapeutics
4.0293 of 5 stars
$1.40
-6.0%
$5.00
+257.1%
+8.3%$293.12M$194.62M-5.00167Earnings Report
Short Interest ↓

Related Companies and Tools

This page (NASDAQ:AQST) was last updated on 5/16/2024 by MarketBeat.com Staff

From Our Partners